Research programme: albumin and antibody drug conjugates - CytRx

Drug Profile

Research programme: albumin and antibody drug conjugates - CytRx

Alternative Names: DK 049

Latest Information Update: 12 Jul 2016

Price : $50

At a glance

  • Originator CytRx Corporation
  • Class Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Research Liver cancer

Most Recent Events

  • 14 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR - 2016)
  • 22 Mar 2016 Interim pharmacodynamics data from a preclinical trial in Cancer released by CytRx
  • 22 Mar 2016 CytRx Corporation plans clinical trials in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top